US stock · Healthcare sector · Biotechnology
Company Logo

Rigel Pharmaceuticals, Inc.

RIGLNASDAQ

1.79

USD
+0.02
(+1.13%)
Market Closed
-3.74P/E
-6Forward P/E
-0.17P/E to S&P500
309.376MMarket CAP
- -Div Yield
Upcoming Earnings
27 Feb-3 Mar
Shares Short
1/13/23
5.64M
Short % of Float
3.83%
Short % of Shares Outs.
3.26%
% Held by Insiders
1.28%
% Held by Institutions
76.32%
Beta
0.74
PEG Ratio
-0.06
52w. high/low
3.52/0.64
Avg. Daily Volume
4.15M
Return %
Stock
S&P 500
1 year
(26.94)
(7.99)
3 years
(27.82)
23.80
5 years
(54.34)
56.27
Scale: |
High
Low
29.25
4.76
14.75
4.19
10.03
6.02
10.21
6.42
11.44
5.37
7.61
2.31
5.00
1.56
5.20
2.02
4.38
1.88
4.47
1.94
4.71
1.96
2.69
1.56
5.24
1.23
5.50
2.30
3.52
0.64
2.04
1.19
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
1.34
0.44
- -
0.02
2.40
0.08
0.03
0.08
0.09
0.33
0.22
0.04
0.28
0.35
0.64
0.88
0.52
Earnings per share
(1.51)
(2.57)
(3.67)
(2.73)
0.73
(1.36)
(1.32)
(1.02)
(1.04)
(0.58)
(0.73)
(0.62)
(0.44)
(0.40)
(0.18)
(0.11)
(0.48)
FCF per share
(1.47)
(1.84)
(2.94)
(2.52)
0.83
(1.13)
(1.18)
(1.00)
(0.80)
(0.27)
(0.81)
(0.62)
(0.37)
(0.26)
(0.32)
0.03
(0.41)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.04
0.03
0.07
0.00
0.07
0.04
0.05
0.01
0.00
0.01
0.01
0.00
0.01
0.01
0.01
0.00
0.00
Book Value per sh.
3.50
2.84
2.89
2.69
3.19
3.73
3.86
2.39
1.46
1.03
0.58
0.80
0.68
0.32
0.20
0.18
0.02
Comm.Shares outs.
25
29
36
41
52
63
75
87
88
88
94
126
161
167
169
169
172
Avg. annual P/E ratio
- -
(4.2)
(5.3)
(2.9)
11.0
(5.7)
(6.8)
(4.5)
(2.8)
(5.5)
(3.7)
(4.7)
(7.7)
(5.5)
(13.9)
(34.9)
(3.7)
P/E to S&P500
- -
(0.2)
(0.2)
(0.0)
0.5
(0.4)
(0.5)
(0.3)
(0.2)
(0.3)
(0.2)
(0.2)
(0.3)
(0.2)
(0.4)
(1.2)
(0.2)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
33
13
- -
1
125
5
2
7
8
29
20
4
45
59
109
149
89
Operating margin
(128.6)%
(631.2)%
(Infinity)%
(14,938.3)%
28.3%
(1,818.3)%
(4,416.8)%
(1,251.3)%
(1,106.0)%
(179.1)%
(342.2)%
(1,775.6)%
(163.3)%
(116.5)%
(26.7)%
(8.4)%
(96.9)%
Depreciation (m)
1
1
1
1
1
2
2
3
2
1
1
0
1
1
1
1
1
Net profit (m)
(38)
(74)
(132)
(112)
38
(86)
(99)
(89)
(91)
(51)
(69)
(78)
(70)
(67)
(30)
(18)
(83)
Income tax rate
- -
- -
0.1%
0.1%
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(3.5)%
0.1%
Net profit margin
(112.4)%
(589.5)%
(Infinity)%
(14,872.9)%
30.3%
(1,810.0)%
(4,392.9)%
(1,245.1)%
(1,101.9)%
(178.1)%
(339.6)%
(1,739.3)%
(158.3)%
(112.8)%
(27.4)%
(12.0)%
(101.3)%
Working capital (m)
97
95
114
118
169
239
290
210
137
95
54
99
109
61
48
91
63
Long-term debt (m)
- -
- -
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
10
30
21
39
Equity (m)
87
82
104
110
166
236
289
208
128
91
55
101
110
54
34
30
(20)
ROIC
- -
- -
(110.4)%
(90.5)%
21.7%
(35.0)%
(33.2)%
(41.3)%
(64.9)%
(52.5)%
(124.6)%
(77.4)%
(63.3)%
(74.5)%
(40.8)%
(12.4)%
(115.2)%
Return on capital
(33.0)%
(64.0)%
(91.9)%
(79.2)%
20.3%
(33.4)%
(31.9)%
(39.4)%
(59.0)%
(39.1)%
(88.6)%
(65.5)%
(50.7)%
(45.1)%
(25.7)%
(7.4)%
(68.1)%
Return on equity
(43.1)%
(90.4)%
(127.1)%
(101.5)%
22.8%
(36.4)%
(34.2)%
(42.7)%
(70.9)%
(56.3)%
(125.8)%
(77.5)%
(64.1)%
(124.3)%
(87.4)%
(59.0)%
416.5%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
(4.5)%
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
3 Nov · 2022 | Q3
All numbers in millions
Total liabilities
$ 135
Total assets
$ 116
Long-term debt
$ 39
Cash and equiv.
$ 30
Goodwill
$ - -
Retained earnings
$ (1,384)
Common stock
173
Enterprise Value
$ 319
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
98
57
125
Receivables
10
16
15
Inventory
1
2
7
Other
9
22
4
Current assets
119
89
154
Acc. Payable
4
4
4
Debt due
- -
9
10
Other
54
29
50
Current liabilities
58
41
64
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
37.39%
261.61%
158.04%
Cash flow
(109.82)%
(34.16)%
(0.23)%
Earnings
(39.77)%
(27.51)%
(12.67)%
Dividends
- -
- -
- -
Book value
(10.73)%
(22.34)%
(15.71)%
Insider Trading
Type
Shares
Date
Santos David A
Award
160,000
01/26/23
Santos David A
Award
50,000
01/26/23
Santos David A
Award
80,000
01/26/23
Schorno Dean L
Award
125,000
01/26/23
Schorno Dean L
Award
50,000
01/26/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
56
16
18
18
109
2021
81
26
22
20
149
2022
17
30
22
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.13
(0.10)
(0.08)
(0.11)
(0.18)
2021
0.23
(0.08)
(0.12)
(0.13)
(0.11)
2022
(0.16)
(0.08)
(0.11)
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Raul Rodriguez
Full-time employees:
165
City:
South San Francisco
Address:
1180 Veterans Blvd
IPO:
Nov 29, 2000
Website:
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing small molecule drugs that enhance the lives of patients with hematologic disorders, cancer, and rare immune diseases. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, its other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Recent News